Mereo Begins Phase 1b/2 Trial To Evaluate Alvelestat In COVID-19-associated Respiratory Disease

(RTTNews) - Mereo BioPharma Group plc (MREO) announced the initiation of a phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease. The trial will be conducted at the University of Alabama. The primary endpoint of the trial is safety and tolerability of alvelestat at day 10, with a safety follow up to day 90.

Alvelestat is an oral small molecule designed to inhibit neutrophil elastase, a key enzyme involved in the destruction of lung tissue.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More